Steris sells into attractive niches

Article Excerpt

The COVID-19 pandemic resulted in short-term disruptions to elective medical procedures, and so demand for Steris’s hospital equipment. But going forward, it remains in a great position to profit from the favourable long-term trend of an aging population. And with two key acquisitions, it has expanded into lucrative new markets. We think this Power Buy is poised to reward our subscribers with solid gains STERIS PLC, $166.34, is a buy. The firm (New York symbol STE; TSINetwork Rating: Extra Risk) (www.steris.com; Shares outstanding: 99.8 million; Market cap: $16.7 billion; Dividend yield: 1.1%) sells sterilization equipment, surgical tables, and other products and services used in hospitals and laboratories. Steris operates in four segments: Healthcare Products (61% of revenues), Applied Sterilization Technologies (19%), Life Sciences (11%) and Dental (9%). Although based in the U.K., it generates 70% of its revenue from the U.S. market. On June 2, 2021, the company completed the acquisition of New Jersey-based Cantel Medical (symbol CMD on New York). The cash and stock deal is valued…